New Delhi, April 14. Prime Minister Narendra Modi has heralded a major transformation in India’s pharmaceutical sector. Speaking on Tuesday, he asserted that the industry is successfully elevating its status from the 'Pharmacy of the World' to a global center for innovation.
The Prime Minister highlighted the nation’s expanding commitment to research-driven growth. He emphasized India's pivotal shift, noting the country's transition from merely supplying affordable generic medicines to becoming a key player in advanced drug development.
Advancing India's Pharmaceutical Value Chain
In a post on X, PM Modi stated, "From the pharmacy of the world to a hub of innovation, India’s pharma sector is moving up the value chain." He detailed that the current government has significantly focused resources on extensive R&D, biologics, biosimilars, and cutting-edge therapies.This strategic pivot means the sector is evolving beyond its historical role. It is moving away from being solely limited to producing generic medicines at scale. Instead, substantial investment is now channeled into advanced research capabilities and complex drug creation.
Policy Support Fuels Innovation Ecosystem
Sharing an article authored by Union Health Minister Jagat Prakash Nadda, PM Modi described the piece as a "must-read retrospection" on India's global ambition. The article underscores how policy support and consistent governmental focus have fundamentally reshaped the industry's trajectory.According to the analysis, the government has been proactive in prioritizing innovation-led growth. This has involved building a supportive ecosystem that actively encourages robust R&D investments.
The Focus on Biologics and Next-Gen Therapies
The discussion heavily features a growing emphasis on specialized segments. Biologics and biosimilars are cited as key areas expected to drive the next crucial phase of growth.Minister Nadda noted that while India was long regarded as the ‘Pharmacy of the World’ due to its generic leadership, the industry is now "ready to shift gears from scale to innovation." The sustained policy push aims to ensure India leads the global pharmaceutical race.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.